News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
Drug Data Delay Offers Actelion Ltd. Bid Shield
February 16, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ZURICH, Feb 16 (Reuters) - Actelion (ATLN.VX), Europe's biggest biotech group, could be immune from takeover until the end of the year when data on a key heart and lung drug is due.
Twitter
LinkedIn
Facebook
Email
Print
Mergers & acquisitions
Europe
MORE ON THIS TOPIC
Insights
Programmable RNA 2.0: Beyond the First mRNA Revolution
February 5, 2026
·
1 min read
·
Jennifer Smith-Parker
Earnings
Novartis Sticks With M&A Strategy of Building Early Pipeline, Searching for Near-Launches
February 4, 2026
·
2 min read
·
Tristan Manalac
Earnings
Merck Bats Away ‘Modest Growth’ Accusations, Touts Broad Pipeline
February 3, 2026
·
2 min read
·
Dan Samorodnitsky
Deals
Roche Keeps the Deals Coming With up to $1.7B SangeneBio RNAi Pact
February 3, 2026
·
1 min read
·
Tristan Manalac
